Xuanye Cao
Postdoctoral Researcher, School of Pharmacy, Fudan University; Founder and CEO of Xuanyan Bio
A postdoctoral researcher at the School of Pharmacy, Fudan University, and founder and CEO of Xuanyan Bio. He received his bachelor's degree in biological sciences from Fudan University in 2016 and his PhD in molecular and cellular biology from Baylor College of Medicine in 2021, followed by postdoctoral training at MD Anderson Cancer Center and work as an algorithm scientist at Baylor Genetics. His company focuses on AI-plus-omics solutions for specific clinical needs, including an AI-based thyroid cancer lymph-node metastasis detection kit now in clinical collaboration with Ruijin Hospital and Zhongshan Hospital. His research integrates epigenetics, AI, omics, and functional validation to study complex diseases, neural tube defects, lung cancer genetics, and aging-related acetylation. He has published 11 JCR Q1 papers as co-first or corresponding author in journals including International Journal of Surgery, Cell Discovery, PNAS, and Journal of Thoracic Oncology, and serves as an advisor or reviewer for Cancers, Genes, BioFactors, and npj Digital Medicine. Within GenAIMed, he can contribute to AI-plus-omics translation, tumor molecular diagnostics, thyroid cancer translation, and complex disease mechanisms.
Wenjin Chen
MD, Physician and Assistant Researcher
A physician and assistant researcher with an MD degree and training experience at Changhai Hospital, Eastern Hepatobiliary Surgery Hospital, Xinhua Hospital affiliated with Shanghai Jiao Tong University School of Medicine, and related research groups at Shanghai University School of Medicine. He has received support from the National Natural Science Foundation of China Young Scientists Fund, China Postdoctoral Science Foundation, and the University of Macau Talent Program, and has been recognized with several academic honors. His research focuses on the tumor microenvironment and tumor heterogeneity. He has published 20 SCI-indexed papers as first author or co-first author, with a cumulative impact factor of 178.6, including 5 papers above IF 10 and a highest single-paper IF of 29.4. Representative work has appeared in Cancer Letters, Microbiome, Journal for ImmunoTherapy of Cancer, and Advanced Materials, with 537 citations and an H-index of 14. He has applied for three national invention patents and contributed to a renal cancer project that received a Huaxia Medical Science and Technology Award.
Quan Cheng
Deputy Director of Neurosurgery, Xiangya Hospital, Central South University; Associate Chief Physician; PhD Supervisor
Deputy Director of Neurosurgery at Xiangya Hospital, Central South University, associate chief physician, associate professor, PhD, postdoctoral fellow in pharmacy, and PhD supervisor. He also serves as Deputy Director of the Hunan International Science and Technology Innovation Cooperation Base for Brain Tumors. His work focuses on glioma and big-data analysis. He has led three general National Natural Science Foundation of China projects, one young scientist project, and multiple provincial outstanding young scholar and key research projects. As first or corresponding author, he has published in Molecular Cancer, Journal of Hematology & Oncology, Signal Transduction and Targeted Therapy, Theranostics, Journal of Experimental & Clinical Cancer Research, eClinicalMedicine, Neurology, and Science Advances. His work has received more than 10,000 citations, with an H-index of 58, 26 ESI Highly Cited Papers, and 6 ESI Hot Papers. He has been listed among the world's top 2% scientists and the ScholarGPS top 0.05% scholars. He serves as Executive Editor-in-Chief of Med Research, Associate Editor of iMeta and iMetaMed, Associate Editor of European Journal of Medical Research, and reviewer for more than 160 journals. Within GenAIMed, he can lead glioma, multi-omics, big-data prognostic modeling, and multicenter neuro-oncology projects.
Guangdi Chu
Department of Urology, The Affiliated Hospital of Qingdao University
A urology researcher at The Affiliated Hospital of Qingdao University, focusing on the application of multimodal big data in diagnosis and surgical treatment of urologic tumors. He serves as a youth editorial board member for iMeta, Med Research, and Cell Proliferation, and reviews for more than 20 SCI-indexed journals including JCI. He has published more than 30 SCI-indexed papers, including first-author or co-first-author work in European Urology and British Journal of Surgery. His work has been incorporated into multiple global clinical expert consensuses on surgical robotics and cited by journals including BMJ and Science Robotics. He has also participated in several national key projects. Within GenAIMed, he can support urologic oncology, surgical robotics, medical education evaluation, and multimodal clinical data projects.
Xinpei Deng
PhD, Department of Urology, Sun Yat-sen University Cancer Center
A PhD from the Department of Urology at Sun Yat-sen University Cancer Center, with long-standing work in tumor drug resistance, tumor immune microenvironment, and multi-omics AI-enabled precision diagnosis and treatment translation. As first or corresponding author, including co-first and co-corresponding roles, he has published in Drug Resistance Updates, iMeta, Journal of Experimental & Clinical Cancer Research, Advanced Science, MedComm, Research, Cell Death & Disease, Cancer Letters, Science China Life Sciences, and other journals. He has an H-index of 31, more than 3,000 citations, and has served as a reviewer for multiple international journals. Within GenAIMed, he can support urologic oncology, resistance mechanisms, immune microenvironment research, multi-omics integration, and AI-enabled precision oncology translation.
Wenyi Gan
Attending Physician, Zhuhai People's Hospital affiliated with Beijing Institute of Technology
An MD and attending physician at Zhuhai People's Hospital affiliated with Beijing Institute of Technology. He graduated from Southern Medical University in 2018 and subsequently received master's and doctoral degrees in orthopedics from Jinan University, under the mentorship of renowned orthopedic experts Zhengang Zha and Xiaofei Zheng. His clinical focus includes joint surgery and sports medicine, with expertise in hip and knee arthroplasty, perioperative management of complex cases, knee ligament reconstruction, meniscus repair, shoulder instability, and arthroscopic minimally invasive procedures. His research bridges orthopedic clinical practice, medical education, and AI, especially generative AI. In recent years, he has published 11 SCI-indexed papers as first author, co-first author, or corresponding author, with a cumulative impact factor of 87.97. Representative work has appeared in International Journal of Surgery, Journal of Translational Medicine, and Journal of Medical Internet Research. His research provides evidence for orthopedic surgical decision-making and explores AI applications in medical education, doctor-patient communication, and telemedicine. Within GenAIMed, he can support joint replacement, sports medicine, orthopedic decision support, AI in medical education, and remote care projects.
Renjun Gu
Associate Professor and Master's Supervisor, Nanjing University of Chinese Medicine
An associate professor and master's supervisor at Nanjing University of Chinese Medicine, with an MD, PhD, and postdoctoral training, and an administrative role in the teaching office of traditional Chinese medicine diagnostics. He serves on several youth committees and professional societies in Chinese medicine, cancer biomarkers, and formula-dose research, and is Editor-in-Chief of Clinical Medical Evidence-Based Research. He has led 8 national, provincial, or ministerial research projects and participated in international collaborations such as the WHO COVID-19 RecMap project. He has published more than 40 SCI-indexed papers as first or corresponding author in journals including Cochrane Database of Systematic Reviews, Research, Advanced Science, Nature Communications, and Oncogene, and has also published an eLetter in Science. Within GenAIMed, he can support cancer multi-omics, AI biomarkers, systematic reviews, and clinical problem framing for data-sharing initiatives.
Aimin Jiang
MD, PhD and postdoctoral researcher, Department of Urology, The First Affiliated Hospital of Naval Medical University
A urology researcher at The First Affiliated Hospital of Naval Medical University, focusing on the tumor microenvironment in urologic cancers. He has led three provincial or ministerial-level projects and received support from the China Association for Science and Technology Young Elite Scientists Sponsorship Program for doctoral researchers. As first or corresponding author, including co-first and co-corresponding roles, he has published papers in eClinicalMedicine, Science Advances, Drug Resistance Updates, Molecular Cancer, and other journals. He has an H-index of 29 and serves on the editorial boards of Med Research, Current Molecular Pharmacology, and Asian Journal of Urology. Within GenAIMed, he can contribute to urologic oncology, tumor microenvironment research, AI-assisted diagnosis and treatment, and multi-omics translational studies.
Anqi Lin
PhD, University of Macau; Department of Oncology, Zhujiang Hospital, Southern Medical University
A cancer researcher at Zhujiang Hospital, Southern Medical University, and Executive Associate Editor of iMeta, with youth editorial roles at hLife and Medicine Advances. Her work focuses on cancer drug resistance, tumor microenvironment regulation, tumor microbiome research, and multidisciplinary AI-assisted oncology diagnosis and treatment, with an emphasis on precision medicine and clinical translation. Over the past five years, she has published more than 110 papers, including first-author or corresponding-author work in JAMA, The Lancet Oncology, Molecular Cancer, iMeta, Gastroenterology, Cancer Communications, Acta Pharmaceutica Sinica B, Advanced Science, Science Advances, Theranostics, Clinical Gastroenterology and Hepatology, Biomarker Research, Gut Microbes, Research, Pharmacological Research, eBioMedicine, eClinicalMedicine, Journal of the National Cancer Center, Cancer Immunology Research, Acta Pharmacologica Sinica, BMC Medicine, and Briefings in Bioinformatics. Her work has received 4,818 citations, with an H-index of 38 and an i10-index of 67.
Xiao Liu
Postdoctoral Research Fellow, Duke-NUS Medical School, National University of Singapore; MD
A postdoctoral research fellow at Duke-NUS Medical School, National University of Singapore, and an MD recognized among Stanford's world's top 2% scientists. His research spans cardiovascular translational medicine, vascular biology, exercise physiology, cardiac rehabilitation, cardiometabolic epidemiology and risk prediction, and AI applications in cardiovascular medicine. He has published more than 100 peer-reviewed papers in journals including European Heart Journal, Cardiovascular Research, and ACS Nano. Multiple papers were ESI Highly Cited Papers, and related work has been cited by American Heart Association and European Society of Cardiology clinical guidelines. He has led National Natural Science Foundation of China and Guangdong Natural Science Foundation projects, received Wiley China highly cited paper and open science contribution awards, and serves as a youth editorial board member for iMeta, Med Research, and Reviews in Cardiovascular Medicine. Within GenAIMed, he can support cardiovascular medicine, cardiac rehabilitation, AI risk prediction, medical education model evaluation, and multicenter real-world research.
Yize Mao
Attending Surgeon, Department of Pancreatobiliary Surgery, Sun Yat-sen University Cancer Center
An MD and attending surgeon in the Department of Pancreatobiliary Surgery at Sun Yat-sen University Cancer Center. After doctoral training at the same center, he remained there for clinical work in pancreatobiliary surgery. He serves as secretary of the Youth Committee of the Pancreatic Cancer Professional Committee of the Guangdong Anti-Cancer Association. His work focuses on mechanisms by which pancreatic cancer fibrosis mediates chemotherapy resistance and includes multiple pancreatic cancer clinical studies. His cisplatin-enhancement study in pancreatic cancer won the Outstanding Paper First Prize at the 2023 Chinese Congress of Integrated Oncology, and his anti-fibrotic therapy study was presented as an ASCO poster in 2024. As first author, co-first author, or corresponding author, he has published more than 30 papers in Cancer Cell, Nature Communications, Journal of Biomedical Science, Molecular Psychiatry, Research, JCO Precision Oncology, Med Research, European Radiology, and Cancer Immunology, Immunotherapy, including 7 papers with IF above 10. Within GenAIMed, he can support pancreatic cancer, tumor fibrosis, resistance mechanisms, clinical cohorts, and AI-assisted treatment response prediction.
Weiming Mou
Physician and PhD Candidate, Department of Urology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
A physician and PhD candidate in the Department of Urology at Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine. His research focuses on tumor microecology and tumor immunity, with particular interest in how the microecological environment relates to tumor development and the immune microenvironment. In recent years, he has published 14 first-author, including co-first-author, papers in Science Advances, Cell Reports Medicine, Journal of Hematology & Oncology, and other international journals. Related work was highlighted by Nature News. His papers have received 1,366 citations, with an H-index of 24. He has served as an academic secretary, contributed to the book Artificial Intelligence in Prostate Cancer Diagnosis and Treatment, and reviewed for journals including Gut Microbes and Journal of Medical Internet Research. Within GenAIMed, he can support urologic oncology, tumor microecology, AI-assisted diagnosis and treatment, and prostate cancer collaborations.
Jingyuan Ning
Single-cell and Spatial Multi-omics Researcher
A researcher focusing on single-cell and spatial multi-omics, as well as AI-driven disease research. He has published 39 papers in journals including Nature Communications, iMeta, Oncogene, Phytomedicine, Research, The Lancet Respiratory Medicine, and The Lancet Microbe, including 23 first-author papers, with a cumulative impact factor above 400. He is currently a responsible editor for Life Conflux and serves as a youth editorial board member for iMeta, Med Research, BIO Integration, Infectious Diseases Research, Journal of Translational Internal Medicine, and Frontiers in Bioscience-Landmark. Within GenAIMed, he can support single-cell and spatial transcriptomics, multi-omics integration, disease classification, and high-quality review writing.
Shengkun Peng
Associate Chief Radiologist and Master's Supervisor, Sichuan Provincial People's Hospital
An MD, associate chief radiologist, and master's supervisor at Sichuan Provincial People's Hospital, selected as a young backbone talent under the Sichuan Health Talent Program. His research focuses on imaging diagnosis of pulmonary diseases and cardiac magnetic resonance imaging techniques and diagnosis. He has led and completed three provincial or municipal projects, one Sichuan Science and Technology Department project, and an institutional high-technology cardiac MRI project. Over the past three years, he has published 11 SCI-indexed papers as first or corresponding author, including two Q1 papers. He serves in several radiology, digital medicine, pulmonary vascular, and regional radiology professional committees in Sichuan and Chengdu. Within GenAIMed, he can support thoracic imaging, cardiac MRI, imaging AI, and multicenter imaging cohort studies.
Chang Qi
PhD candidate, Faculty of Informatics, TU Wien
A PhD candidate in the Faculty of Informatics at TU Wien, with previous experience at Bilibili, The Sixth Affiliated Hospital of Sun Yat-sen University, and The University of Hong Kong. His research focuses on large language models, computational drug discovery, and neuroscience-inspired AI algorithms, combining engineering practice, medical application scenarios, and algorithmic research. He has published papers at leading AI conferences including ICLR and ICML, as well as journals such as npj Digital Medicine and Briefings in Bioinformatics. Within GenAIMed, he can support LLM evaluation in medicine, complex disease expert-agent systems, AI drug discovery, model reasoning assessment, and interdisciplinary algorithm design.
Luxiang Shang
Associate Researcher and Attending Physician, The First Affiliated Hospital of Shandong First Medical University
An associate researcher and attending physician at The First Affiliated Hospital of Shandong First Medical University, also known as Shandong Provincial Qianfoshan Hospital, with a background in cardiovascular medicine and postdoctoral training at Shandong Academy of Medical Sciences. He has led National Natural Science Foundation of China Young Scientists Fund, China Postdoctoral Science Foundation, Shandong postdoctoral fund, and key laboratory open projects. His work focuses on atrial fibrosis, atrial fibrillation, cardiomyocyte autophagy, PPAR-gamma ubiquitination and degradation, cardiovascular-kidney-metabolic syndrome, and health management cohorts. He serves as a youth editorial board member of Cardiovascular Innovations and Applications and Reviews in Cardiovascular Medicine and reviews for multiple Chinese medical journals. He has published 24 SCI-indexed papers as first or corresponding author and 15 Chinese-language papers. Within GenAIMed, he can support cardiovascular chronic disease, CKM syndrome, LLM medical knowledge evaluation, real-world health management data sharing, and multicenter chronic disease studies.
Hao Sun
Researcher, University of London; Biomedical Engineering and Nanomedicine
A researcher at the University of London, with a PhD from the Spanish National Center for Cardiovascular Research and the Autonomous University of Madrid, and joint training at Harvard Medical School. He has more than 7 years of overseas study and work experience and has led research projects in the United Kingdom and Spain. His research covers biomedical engineering, AI-medicine intersections, nanomedicine, and nanodrug delivery. He has published more than 30 SCI-indexed papers in journals including Molecular Cancer, npj Digital Medicine, Materials Science and Engineering R, New Phytologist, Advanced Healthcare Materials, International Journal of Surgery, and Journal of Inflammation Research, with several papers among the ESI top 1%. He has delivered invited oral or keynote presentations at international meetings and institutions, chaired sessions, and served as a youth editorial board member or reviewer for journals including iMeta, Nature Communications, and International Journal of Biological Macromolecules. Within GenAIMed, he can support AI-medicine intersections, nanodrug delivery, tumor materials medicine, and high-level review projects.
Bufu Tang
Interventional Oncology, Zhongshan Hospital, Fudan University; Graduate Supervisor
A graduate supervisor in the Department of Interventional Radiology at Zhongshan Hospital, Fudan University, focusing on clinical and mechanistic research in interventional treatment of malignant tumors. He has led or participated in National Natural Science Foundation of China projects, National Key Research and Development Program projects, and multiple provincial or ministerial projects. He was recognized with the CCI Young Interventional Radiologist Award and listed among the world's top 2% scientists. In recent years, he has published more than 70 SCI-indexed papers as first or corresponding author in Science Advances, iMeta, Nature Communications, Molecular Cancer, Military Medical Research, Acta Pharmaceutica Sinica B, and Trends journals, with an H-index of 30. He serves as an editor or youth editorial board member for journals including BMC Medicine and iMeta, Executive Editor-in-Chief of TransMed, and committee member of the Artificial Intelligence Committee of the China Anti-Cancer Association.
Hank Z.H. Wong
Department of Rehabilitation Sciences, The Hong Kong Polytechnic University; Master Supervisor in Clinical Oncology, Yangzhou University Medical College
A rehabilitation sciences researcher at The Hong Kong Polytechnic University and a master supervisor in clinical oncology at Yangzhou University Medical College. He serves as Executive Associate Editor of iMeta and iMetaOmics, Executive Editor-in-Chief of iMetaMed, and Executive Editor-in-Chief at FAR Press. He is also an editorial board member of Discover Oncology and Discover Public Health and has reviewed for more than 130 international journals. He has published 58 SCI-indexed papers as first or corresponding author in journals including Cancer Research, Cell Reports, and iMeta, with an H-index of 18. Within GenAIMed, he can support oncology rehabilitation, AI-assisted clinical assessment, medical publishing collaboration, and interdisciplinary review projects.
Dongqiang Zeng
Associate Professor, Shenzhen Hospital, Southern Medical University
An associate professor at Shenzhen Hospital, Southern Medical University, and an Elsevier 2025 world's top 2% scientist. He serves as a youth editorial board member of MedComm-Future Medicine and iMeta, and holds committee roles in the Guangzhou Medical Association Oncology Branch, Guangdong Pharmaceutical Association Tumor Immunotherapy Committee, and Guangdong Medical Association Gastrointestinal Oncology Group. His research focuses on tumor RNA splicing and mRNA vaccines. He received the 2023 Chinese Medical Science and Technology Award, the 2021 AACR Best Research Award, and the 2019 AACR-KCA Young Investigator Award. As first or corresponding author, he has published 12 SCI-indexed papers in Advanced Science, Cell Reports Medicine, Med, Cell Reports Methods, CIR, JAMA Network Open, and other journals, including 4 ESI Highly Cited Papers and 1 ESI Hot Paper. His work has received more than 4,500 citations, with a Google Scholar H-index of 22. He has led a National Natural Science Foundation of China Young Scientists Fund project, a Guangdong provincial young scientist project, and a Guangzhou science and technology project. Within GenAIMed, he can contribute to tumor immunity, multi-omics, mRNA vaccines, and immunotherapy prediction.
Qing Zeng
Deputy Director, Department of Rehabilitation Medicine, Zhujiang Hospital, Southern Medical University; Chief Physician
A young top talent in health under the Guangdong Special Support Program, temporary program and policy officer at the National Natural Science Foundation of China, Deputy Director of the Rehabilitation Medicine Center and Deputy Director of the Scientific Research Office at Zhujiang Hospital, Southern Medical University, and a chief physician with both academic and professional master's supervision roles. He leads laboratories in intelligent brain-function rehabilitation and neural repair, and has more than 19 years of clinical, educational, and research experience in rehabilitation medicine, including neurological, pediatric, cardiopulmonary, and cognitive rehabilitation. His research focuses on stem cells/exosomes and neurorehabilitation, as well as AI, wearable devices, brain-computer interfaces, and neuromodulation in rehabilitation medicine. He has led two National Natural Science Foundation of China projects, six provincial or departmental projects, and multiple rehabilitation-related research programs, with more than 50 SCI-indexed papers, books, patents, and consensus contributions. Within GenAIMed, he can support rehabilitation medicine, neural repair, brain-computer interface research, wearable-device studies, AI-assisted rehabilitation assessment, and remote rehabilitation trials.
Hengguo Zhang
Associate Professor, PhD Supervisor, and Academic Vice Dean, School and Hospital of Stomatology, Anhui Medical University
A stomatology PhD, associate professor, PhD supervisor, Deputy Secretary of the Anhui Medical University Youth League Committee, and Academic Vice Dean of the School and Hospital of Stomatology at Anhui Medical University. He has been a visiting scholar at the State Key Laboratory of Oral Diseases, Sichuan University, and was selected as an Anhui Young Top Talent and Hefei Class D Talent. He serves on national and provincial committees in digital dentistry, oral medical devices, and oral implantology. His research focuses on stem-cell epigenetics and jawbone aging repair, oral microbiology and systemic diseases, and AI in stomatology. Over the past five years, he has published more than 10 SCI-indexed papers as first author or last corresponding author in CAS Q1 or top journals including Cell Death & Differentiation, Bone Research, International Journal of Oral Science, and iMeta, with 4 ESI Highly Cited or Hot Papers and an H-index of 20. He has co-edited books, filed 5 national invention patents and 6 software copyrights, and led National Natural Science Foundation of China general and young scientist projects. He serves as Executive Associate Editor of iMeta, editorial board member of Scientific Reports, Associate Editor of Advanced Genetics, handling editor of Phenomics, guest editor of Journal of Nanjing Medical University, and youth editorial board member of hLife, Genes & Diseases, and VIEW. Within GenAIMed, he can support oral AI, CBCT image analysis, oral implantology, aging repair, and multimodal clinical data projects.
Lin Zhang
Research Fellow and PhD Supervisor, Monash University
An MD, research fellow and PhD supervisor at Monash University, and PhD supervisor at the Southeast University-Monash University Joint Graduate School. He is a Fellow of the Royal Society for Public Health, a committee member of the Applied Evaluation and Assurance Committee of the Chinese Health Information and Healthcare Big Data Association, Deputy Secretary-General of the Active Aging Health Committee of the China Association of Gerontology and Geriatrics, and a GBD collaborator. He has led multiple international and domestic clinical studies and published more than 280 academic papers, with an H-index of 44 and more than 7,500 citations. His work has appeared in The Lancet, BMJ, The Lancet Haematology, The Lancet Digital Health, The Lancet Rheumatology, Nature Reviews Gastroenterology & Hepatology, Nature Aging, Nature Communications, Gastroenterology, Gut, Journal of Hematology & Oncology, Liver Cancer, and Cancer Letters. He received the University of Melbourne Best Research Team Award, the Victorian International Education Award, the Australia-China Alumni Award for Research Excellence, and the Monash University Research Excellence Award. Within GenAIMed, he can support global burden of disease research, public health big data, healthy aging, precision medicine, and responsible generative AI.
Wangzheqi Zhang
Department of Anesthesiology, Naval Medical University
A researcher in the Department of Anesthesiology at Naval Medical University, focusing on cell death mechanisms, post-translational protein modification, sepsis, and tumor immunity, with emphasis on how these mechanisms connect to disease. Over the past two years, he has published more than 70 papers as first or corresponding author, including co-first and co-corresponding roles, in Trends in Immunology, Cell Death & Differentiation, Drug Resistance Updates, Experimental & Molecular Medicine, iMeta, Exploration, Research, and Physical Life Reviews. His publications include 2 ESI Highly Cited Papers and 1 ESI Hot Paper. He serves as Executive Editor of Perioperative Precision Medicine and youth editorial board member for Current Molecular Pharmacology, Research, and Bio Integration. Within GenAIMed, he can support mechanism mapping, inflammatory immunity, perioperative medicine, and high-level review projects.
Zhe Zhang
Medical Physicist, Department of Radiation Oncology, Peking University Shenzhen Hospital; PhD in Computer Science, University of Liverpool
A medical physicist in the Department of Radiation Oncology at Peking University Shenzhen Hospital, with a PhD in computer science from the University of Liverpool. He serves as a youth editorial board member of Intelligent Oncology and Meta-Radiology, and reviews for international journals including Academic Radiology, Medical Physics, and Physics and Imaging in Radiation Oncology. His research focuses on AI in oncology, multimodal medical image analysis, radiomics, and physical and biological optimization in radiotherapy. He has published SCI-indexed papers in journals including Physics and Imaging in Radiation Oncology, Translational Lung Cancer Research, and npj Digital Medicine. He translated the oncology monograph Practical Guide to Breast Cancer Radiation Therapy: Technical Applications, holds two utility model or invention patents, has participated in National Key Research and Development Program and National Natural Science Foundation of China projects, and has led institutional key projects. Within GenAIMed, he is well suited to lead multicenter imaging AI, radiotherapy dose planning, and imaging data standardization.
Lingxuan Zhu
PhD Candidate, Southern Medical University
A PhD candidate at Southern Medical University, focusing on tumor microecology, tumor immunity, and AI applications in clinical medicine. In recent years, he has published multiple first-author, including co-first-author, papers in international journals including Cell Reports Medicine, Science Advances, and Journal of Hematology & Oncology. He has also been invited to review for journals including MedComm and Journal of Medical Internet Research. Within GenAIMed, he can support tumor microecology, immunotherapy response prediction, AI clinical evaluation, medical large language model applications, and multi-omics interdisciplinary research.